The board will be tasked with providing guidance as the company transitions to clinical studies for its therapeutics and diagnostics created to act at the site of disease in the gastrointestinal tract. Additionally, each member will help guide the strategy and development of Progenity’s gastrointestinal health programs.
The board members include William Sandborn, MD; Geert D’Haens, MD, PhD; Bruce Sands, MD; and Séverine Vermeire, MD, PhD.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
